Skip to main
IDYA
IDYA logo

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 64%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences Inc is experiencing a positive shift in its financial outlook, as indicated by an increased probability of success (PoS) for the darovasertib program to 70%, alongside promising preclinical and early clinical results demonstrating anti-tumor responses in metastatic uveal melanoma. The synergy observed between darovasertib and crizotinib highlights a strengthened efficacy profile, suggesting improved safety and tolerability outcomes, which could significantly enhance the company's revenue projections beyond the current estimate of ~$3.2 billion. With ongoing Phase 3 trials and multiple catalysts on the horizon, combined with strong clinical data showing meaningful survival benefits, IDEAYA's portfolio appears well-positioned to capture value in the oncology market despite the niche nature of uveal melanoma.

Bears say

The analysis of IDEAYA Biosciences Inc reveals several fundamental concerns contributing to a negative outlook on its stock. Key risks include the company's non-revenue-generating status, unpredictability of future revenues and expenses, and potential delays or limitations in commercialization due to negative trial outcomes, unexpected safety signals, or adverse regulatory decisions. Furthermore, the potential failure of IDE397 and IDE849 to yield competitive clinical results, along with the concentration risk associated with darovasertib's success in clinical and commercial execution, heightens the uncertainties surrounding IDEAYA's market positioning and investor confidence.

IDYA has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 64% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 11 analysts, IDYA has a Buy consensus rating as of Dec 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.